BIO Bio-Rad Laboratories: Market Capitalization to Book Value Ratio

Official company branding of Bio-Rad Corp (BIO)

Bio-Rad Laboratories (BIO) is valued as a reliable industry veteran trusted by scientists, despite a moderate pace of innovation. The company implements ESG principles by developing energy-efficient equipment and less harmful reagents. The price action vector available for analysis on GURU.Markets is fixed at 1.40. The business's operational resilience relies on an extensive system of global plants that guarantee assembly precision and supply stability.

Bio-Rad Corp (BIO): Capitalization to Book Value Ratio from 07/04/2022 to 10/27/2026
Core merchandise of Bio-Rad Laboratories, Inc.

This indicator reflects the market value premium of Bio-Rad Laboratories (BIO) relative to its net assets, allowing for an assessment of the business's overvaluation against its historical median. By analyzing the chart of the market cap to book value ratio, an investor can identify liquidity anomalies, which in the case of Bio-Rad Laboratories (BIO) are smoothed out by global sales diversification and the high profitability of clinical diagnostic systems.

Main competitors

A (Agilent Technologies) - Market Value to Book Value Ratio|questdiagnostics.com (DGX) - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio ILMN (Illumina)|Market-to-Book Ratio Exact Sciences Corp|Market Capitalization to Book Value Ratio PerkinElmer RVTY|Capitalization to Book Value Ratio Anbio Corp (NNNN)|Market Capitalization to Book Value Ratio SHC (Sotera Health Company)|quidel.com - Market Capitalization to Book Value Ratio|OPKO Health (OPK) - Market Value to Book Value Ratio|CDNA - Capitalization to Book Value Ratio|MRVI: Market Capitalization to Book Value Ratio|FLGT (Fulgent) - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Standard BioTools Inc.|Market Value to Book Value Ratio cytekbio.com (CTKB)|OraSure - Market Cap to Net Assets Ratio|Market-to-Book Ratio XGN (exagen.com)|Market Value to Book Value Ratio MDXH|Market Capitalization to Book Value Lucid Diagnostics, Inc LUCD|Market Capitalization to Book Value Ratio PRE (Prenetics Global Ltd)|IMDX: Market Capitalization to Book Value|trinitybiotech.com - Market Value to Book Value Ratio|ProPhase Labs Inc (PRPH) - Market Capitalization to Book Value|Market Capitalization to Book Value Ratio Ainos Corp|Market Value to Book Value Ratio CoDx|HSCS (Heart Test Laboratories) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value BMRA (biomerica.com)|CDIO: Market Value to Book Value Ratio|VRAX - Market-to-Book Ratio|Market Cap to Net Assets Ratio BJDX|AWH: Market Value to Equity Ratio|Market Value to Book Value Ratio Accelerate Diagnostics AXDX|CENTOGENE (CNTG) - Market Value to Book Value|ENZ (Enzo Biochem Inc.) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio Fresh2|Market Capitalization to Book Value Ratio Genetic Technologies GENE|Capitalization to Book Value Ratio 23andMe Inc ME|Market Cap to Net Assets Ratio Psychemedics